Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience

BACKGROUND: In 2011, we reported the outcomes of pancreatic cancer (PC) patients enrolled in phase I trials at our institution from 2004 through 2009. At the time, gemcitabine and erlotinib were the only Food and Drug Administration-approved drugs for PC and median overall survival (OS) from consult...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Goldstein, Jennifer B., Tang, Chad, Hess, Kenneth R., Hong, David, Subbiah, Vivek, Janku, Filip, Fu, Siqing, Karp, Daniel D., Naing, Aung, Tsimberidou, Apostolia Maria, Wheler, Jennifer, Zinner, Ralph, Javle, Milind, Varadhachary, Gauri R., Wolff, Robert A., Fogelman, David R., Meric-Bernstam, Funda, Piha-Paul, Sarina A.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675623/
https://ncbi.nlm.nih.gov/pubmed/29152071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19897
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados